*Sabby Management Increased 10% Stake In Ability Inc.
Insiders know ABIL is worth much higher than the current level in the future.

ABIL is a traders favorite,Load up on any downticks,this low float monster will hit $20 next acquisition news.
Ability Inc.(ABIL) is solidifying its position through this deal as
one of the best and critical Cellular Interception company.

ABIL Needs Working Capital$$$ to Make an Acquisition Deal, It's Perfectly
normal offering, this is a great buying opportunity at lower stock price,
load up this low float monster on any downticks and hold for next $20
on the deal news; ABIL said -- "the deal will no longer require it to share revenue with the supplier once finalized"

According to Analysists-Upcoming Presentation Would Be Whole Different Thing Compared to Previous Ones!!
VTVT has been working on a different delivery method to refine the previous study and this different options could change
the way in which Alzheimer’s is treated. Load up this cheap shares as much as you can NOW, Once they release a final data
VTVT will hit $50~$100.

----------------------
vTv Therapeutics to Deliver Two Presentations at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
BUSINESS WIRE 10:30 AM ET 10/16/2018
Results of the Azeliragon Phase 3 STEADFAST Trial to be Presented during Oral Session

Subgroup Data Discussing the Effect of Azeliragon in Patients with Dementia and Diabetes to be Presented during Poster Session

HIGH POINT, N.C.--(BUSINESS WIRE)-- vTv Therapeutics Inc.(VTVT) , a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced that it will deliver an oral presentation and present a poster at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) conference on October 24-27, 2018 in Barcelona, Spain.

The oral presentation will detail the results from the phase 3 STEADFAST study of azeliragon in patients with mild Alzheimer’s disease. Details of the oral presentation are listed below:

Oral Presentation Title: “Safety and efficacy results from the phase 3, multicenter, 18-month STEADFAST trial of azeliragon in patients with mild Alzheimer’s disease”

Date and Time: Fri., Oct. 26, 2018 at 3 p.m. CEST (9 a.m. EST)
In addition, a subgroup analysis from the company’s STEADFAST trial will be presented as a poster. Details of the poster presentation are listed below:

Late-Breaking Poster Title: “Is RAGE the missing link between diabetes and dementia? Results from a subgroup analysis of the STEADFAST trial”

Poster Number: LBP18
Category: Clinical Trials: Results
Date and Time: Wed., Oct. 24, 2018 (3 p.m. CEST) through Sat., Oct. 27, 2018 (3 p.m. CEST)

About vTv Therapeutics(VTVT)
vTv Therapeutics Inc. (VTVT) is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and diabetes as well as treatment of inflammatory disorders.

About STEADFAST
The STEADFAST study, two independent and identical randomized, double-blind, placebo-controlled Phase 3 trials (Part A and Part B), was designed to investigate the safety and efficacy of azeliragon as a potential treatment for patients with mild Alzheimer’s disease. The 18-month study targeted enrollment of 800 patients (400 in each trial). The first trial enrolled patients in the United States and Canada who had a clinical diagnosis of mild Alzheimer’s disease and an MRI consistent with this diagnosis. Enrollment of the second trial included study sites in the United Kingdom, Ireland, Australia, New Zealand and South Africa.

EARS Will hit $2,50 Tomorrow & $3.50 by Wednesday
Load on any downticks!!! OGEN went Up $4.40(after HR Trading)
from $0.60 on Phase2 Clinical data last week!!

Forget Toxic Massive-$400M Diluter-TLRY &India-SCAM IGC, NBEV is Only HOT & Legit-CBD Player !!
NBEV Is TLRY in making Starting Nextweek! DEBUT FIRST CBD-Product on 10/8/2018!!!! Load Up NBEV NOW!!
They're In Talks With Retailers for CBD Distributions Starting Next week !!!!

NBEV Set to DEBUT FIRST CBD-Product at The North American Convenience Store Show on 10/8/2018!!!! NBEV Slated to Reach $20~$30 After New Product lines!!/ Possible Announcement Alliance, Distribution Agreement/ Deal Pending.

NEW AGE BEVERAGES CORPORATION (NASDAQ: NBEV), the Colorado-based organic and natural healthy functional beverage company intending to become the world's leading healthy beverage company, today announced that it intends to debut its portfolio of CBD infused beverages at the upcoming North American Convenience Store show (NACS) to be held at the Las Vegas Convention Center on October 7-10, 2018.

Given the growing awareness of the potential health benefits of CBD, the New Age Health Sciences Division evaluated the data and science supporting the emerging segment. As a result of that assessment, New Age began testing a CBD-infused beverage earlier this year in its home market in Colorado. Based on the learnings gained in the test market and the increased consumer acceptance of the segment, New Age has decided to expand its presence in the category. The Company has taken the learnings it gained in product formulation and taste, efficacy and dosage, and consumer communication and has developed a portfolio of CBD-infused beverages. Now, coupled with the increased interest from major retailers in North America, New Age intends to unveil its portfolio and category insights with select retail partners at the NACS show on October 8th.

According to the Brightfield Group, the Global market for CBD will top $22 Billion with the next 4 years. Non-psychotropic CBD is one of the most medicinal compounds in the cannabis plant, reportedly helping with everything from arthritis to epilepsy and cancer, and is seen by many as a natural remedy instead of a pharmaceutical or narcotic drug. The 2018 Farm Bill, which was recently passed by both the House and Senate, would likely legalize CBD for farmers across the country and allow it for sale nationally in all channels.

New Age will be meeting with some of the major retailers in the country at NACS on October 8-10th and taking orders on a first come, first serve basis, given anticipated demand. New Age's Health Sciences Division is overseeing and carefully controlling production, quality, and its supply chain and sales channel partners given the importance of efficacy and quality control in the end product.
Zach Ross, Marley Marketing Manager at New Age commented, “We believe we have developed unique consumer insights and accessed superior technology in CBD-infused beverages over the past year, and we are excited to share those insights with key retail partners. We believe we are in a position to bring national leadership to this emerging growth segment, and intend to launch the most efficacious and safe CBD-infused products for consumers, with the most responsible marketing and education to a segment that has potential to be transformative to healthy functional beverages.”

Marijuana/CBD Beverage Stocks Plunges after PepsiCo SaysNO Pot-Plans--CNBC-10/2/ 2018
Shares of volatile cannabis company Tilray dropped as much as 20 percent Tuesday after PepsiCo told investors it has no plans to invest in pot. "I think the difficulties in investing in that category, particularly in the U.S., where federally these things are still not legal, are quite a considerable challenge," Pepsi's CFO said. Cannabis stocks fell across the board Tuesday after PepsiCo PEP told investors that the food and beverage giant said it has no plans to invest in marijuana.

Marijuana/CBD Beverage Stocks Plunges after PepsiCoSays NO-Pot Plans--CNBC-10/2/ 2018
Shares of volatile cannabis company Tilray dropped as much as 20 percent Tuesday after PepsiCo told investors it has no plans to invest in pot. "I think the difficulties in investing in that category, particularly in the U.S., where federally these things are still not legal, are quite a considerable challenge," Pepsi's CFO said. Cannabis stocks fell across the board Tuesday after PepsiCo PEP told investors that the food and beverage giant said it has no plans to invest in marijuana.

Stupid CEO is KEEP diluting, Look at the massive volumes yesterday & today.

OGEN Presenting at the Conference Today and Another One TOMORROW!!
The new antibiotic DRUG DATA Will be Good~ Stock will Hit $2~$3 After Good Drug Data News from Conference
With A Tiny 11M Market Cap, OGEN is headed to old High $4.70 Get In Now $$$$$$$$$

Yeap expect debt deal closing news with a 1:100 reverse split announcement.

Another Reverse Split Announcement Any Day~
I know they have the approval to do up-to 100:1 this time.

Sell This PIG, ATM Offering at $0.68, They will Dilute Till 0.68, Take your Profits GET OUT !!!

ANALYST Downgraded NBEV to Hold from Buy;
Analyst Actions: Maxim CUTS New Age Beverages to Hold from Buy; Shares Slide 12%
MT NEWSWIRES 7:25 AM ET 9/21/2018

ANALYST Downgraded NBEV to Hold from Buy;
Analyst Actions: Maxim CUTS New Age Beverages to Hold from Buy; Shares Slide 12%
MT NEWSWIRES 7:25 AM ET 9/21/2018

Unsustainable PD Stock will Fall Back to $4.85 According to Extreme Over Bought Chart.

Conservative ANALYST SAYS NIO is worth Double $$$$$$$$
https://markets.businessinsider.com/news/stocks/tesla-of-china-nio-stock-price-market-cap-could-double-five-years-2018-9-1027535891

Conservative ANALYST SAYS NIO is worth Double $$$$$$$$
https://markets.businessinsider.com/news/stocks/tesla-of-china-nio-stock-price-market-cap-could-double-five-years-2018-9-1027535891

NIO earnings Sept 30-- TSLA made its first big move after their first earnings report. NIO produces 7000 cars in this current quarter, it took TSLA 3 years to arrive at that level of production. My call is 40$ by end of year. Long and stong!

So far we have for NIO:
June 2018 produced 272 delivered 100
July 2018 produced 831 delivered 381
Aug 2018 produced 1296 delivered 1121

And, in Sep the delivered will climb up to 3000, according to their CFO. I would say pretty impressive growth for a new player...
Less

Did you know TESLA did not make a Retail-Car Till 5-Years After it's IPO? Yet TSLA was Trading even at an INSANE price, Currently,TSLA is not profitable either at over $50B Market Value!! NIO is far ahead of where Tesla stood after its first four years. NIO will hit instant $30 once pending news hit the market. NIO has more than 17,000 ES8(=sport utility-EV like Tesla’s Model X.) reservations pending! AND plans to launch its second SUV, the ES6 later in 2018~ Load up on any downticks & hold for long term rewards !!!

CHINESE Gov't Planning to BAN ALL GASOLINE CARS SOON and Switch to Electric-Vehicles Due to the Severe Pollutions:
NIO Has a Mega-Huge Potential to be a $100 stock by 2019.
https://www.theverge.com/2017/9/10/16284866/china-ban-fossil-fuel-cars
China is the world’s largest market for automobiles, with over 28 million vehicles sold in 2017, a number that has continued to rise in recent years. Bloomberg notes that China has worked to encourage the growth of its Electric-Vehicle market through subsidies as it works to cut its carbon emissions.
More
Regulators are working to prepare a timeline to end sales and production

Load Up on any downticks!!! The COURT APPROVAL NEWS ANYDAY NOW~
BONTQ will hit $.0.20 on NEWS!
https://lancasteronline.com/business/local_business/indiana-firm-completes-bon-ton-asset-purchase-plans-to-revive/article_015dd2c0-b523-11e8-889d-03fc966618d8.html
A U.S. Bankruptcy Court judge on Monday approved an Indiana company’s proposed purchase of The Bon-Ton’s brand names and customer data for $900,000.

Oversold CVSI poised to shoot up to $5 on PENDING NEWS MONDAY.
Load up as much as you can before mkt close today.

Pending NEWS on MONDAY, the stock is way oversold Load up as much as you can today.

Stay Away from PPCB, The Massive Toxic Convertible Notes Will Wipe Out Your Holding to $.0004
*They will be dumped MASSIVE 4 Billion shares into the market. SEC Filed-8/29/2018
The increase in the number of authorized shares of our common stock, par value $0.001 per share, from 400,000,000 to 4,000,000,000.

The conference-hype party is OVER, The anemic Earning Report will crush the stock,plus stock will be diluted back to $0.004 level coming months
SEC filed 8/29/2018--PPCB announced to increase in the number of authorized shares of our common stock, par value $0.001 per share, from 400,000,000 to 4,000,000,000..

It’s all about the Farm Bill being signed so that CVSI could qualify as its a cannabis company. And cannabis is still federally illegal. The Farm Bill will change the definition of hemp in terms of its relationship to cannabis. Then and only then will it qualify. The timing is good as it must be signed (or die) by September 30th.

Yawnnn~ it's only 53K for now( this small amount won't affect the PP)
and the rest of C/N are due in 2019 if read:


Buyer desires to purchase and the Company desires to issue and sell, upon the terms and conditions set forth in this Agreement a convertible note of the Company, in the form attached hereto as Exhibit A, in the aggregate principal amount of $53,000.00 (together with any note(s) issued in replacement thereof or as a dividend thereon or otherwise with respect thereto in accordance with the terms thereof, the “Note”), convertible into shares of common stock, $0.001 par value per share, of the Company (the “Common Stock”), upon the terms and subject to the limitations and conditions set forth in such Note.

Today midday dip was a “GIFT” buying opportunity. PPCB should be on its way back to this year’s highs of $0.77 a share.
Propanc Biopharma Inc (PPCB) stock has bounced back to life on news the company has entered a national phase on two key patents for cancer treatment. Also PPCB benefit from the "Right to Try Act"President Trump signed aimed at allowing terminally ill patients a right to try a drug that is not currently FDA approved. This is a really major development for innovative biotech like PPCB.

Price action points to further movements on the upside as the upward momentum continues to gather pace, the stock should be on its way back to this year’s highs of $0.77 a share.

September,4-2018- PPCB is headed back to $0.77
Propanc Biopharma Inc (PPCB) stock has bounced back to life on news the company has entered a national phase on two key patents for cancer treatment.
Investor confidence in the stock has ticked higher on the strides the company has made on the development of the two key patents targeting cancer treatments. The stock is currently trading in a steep uptrend at the back of high turnover in traded shares.

Price action points to further movements on the upside as the upward momentum continues to gather pace, the stock should be on its way back to this year’s highs of $0.77 a share.

Recent Developments
Entering a national phase on two essential patents is the latest catalyst pushing the stock up the charts. The first patent details a method of eradicating cancer stem cells while the second cancer patent covers compositions for the treatment of solid tumors.
The biopharmaceutical company has filed a patent application for the two methods in major global jurisdictions and indication of how confident it remains about the new systems being a game changer in the medical world.
The patent applications will cover the company’s lead product candidate PRP, currently being used in cancer stem cell therapy.

“We have been working with PRP and cancer stem cells for several years, and our pre-clinical studies demonstrate that PRP appears to have a significant effect on killing these cells off, which are the main drivers of cancers. This is highly important because killing cancer stem cells reduces the risk of tumor recurrence, clinically,” said Dr. Julian Kenyon, Propanc BioPharma Chief Scientific Officer.
The patent filing comes months after the clinical stage company held a scientific advice meeting with the Medicines and Healthcare Products Regulatory Agency MHRA in the U.K. Discussions in the meeting centered on the investigational medicinal product program for PRP marking an essential step as the company continues to push for support and approval for the first CTA in the U.K.

Buoyed by achievements on the clinical development front the company has engaged the service of financial advisors as it looks to restructure and strengthen its balance sheet. The restructuring drive should allow the company to strengthen its balance sheet as it looks to advance PRP into the first-in-human study.
Propanc has already received an invite to make a presentation at the 25th Annual Newsmakers in the Biotech Industry. The conference is to be held on Friday, September 7th, 2018. The invitation to the conference presents a unique opportunity for the for the company to convey its story and products to an audience of international investors
“Our focus will be to present the recent advancements of our lead product candidate, PRP, and its effects against cancer stem cells as a way to control metastasis, which is the main cause of patient death from cancer,” said James Nathanielsz, Propanc Biopharma’s Chief Executive Officer.

Analyst Said CITRON's Note Contained"Unfounded Allegations"and Was Biased--US cannabis stock
Weed stocks rally ahead of holiday weekend, Tilray set to hit record high--MARKETWATCH-8/31/2018

Weed-maker Tilray Inc.(TLRY) rebounded Friday, rising 10% in afternoon trading, hitting an intraday record. If Tilray(TLRY) closes above $62.13 it will reach a record high. The stock is trading at $65.08 as of 1:46 p.m. Eastern Time. Other cannabis stocks listed on major U.S. exchanges also rallied in Friday trading. Cronos Group Inc.(CRON) was up 8.7% Friday, after Citron Research made a short call Thursday that send shares plummeting; Analyst said the Citron note contained "unfounded allegations" and was biased. Canopy Growth Corp.(CGC) also rose Friday, gaining 3.6%. While pot is illegal under U.S. federal law, Canada is set to legalize the drug Oct. 17. Horizon Marijuana Life Science Index ETC , which tracks more than 20 cannabis companies in North America and trades on the Toronto Stock Exchange, gained 1.3% Friday.

*GMP Securities analyst Martin Landry said the Citron’s claims were “unfounded and biased.”

Uplisting Still pending, CVSI has been $3 over for past 30 days & easily can maintain another 60 days!

CV Sciences,Inc. Provides Corporate Update to Shareholders--8/30/2018
LAS VEGAS,Aug.30,2018(GLOBE NEWSWIRE)--CV Sciences,Inc.(CVSI) (the “Company”, “CV Sciences”, “our” or “we”) would like to assure our shareholders that we are keenly aware of recent market activity and certain disinformation disseminated by persons holding short positions in our stock.

“As many of our shareholders are aware, our Company has been victimized by campaigns run by short sellers in order to depress our stock price, so they could make financial windfalls,” stated Joseph Dowling, Chief Executive Officer of CV Sciences.
“We are also aware that at least one such group has boasted on social media platforms about its financial returns since their release of misleading information regarding the Company’s patent prosecution and drug development efforts.”
Mr. Dowling continued, “While we don’t normally comment on our stock price or performance, it is important to stress that nothing has fundamentally changed in our business.
We continue to deliver solid financial results, and we remain very confident in our prospects.”
Over the last year, the Company has achieved numerous milestones and market-leading fundamentals. Some notable items include:

*Record-breaking Q2 2018 financial results including revenues of $12.3 million, net income of $3.2 million and adjusted
EBITDA of $3.8 million.

*Record-breaking first half 2018 financial results including revenues of $20.4 million, net income of $3.8 million and adjusted EBITDA of $5.6 million.

*Recent repayment of remaining debt obligations resulting in a much stronger, debt-free balance sheet.

*Market-leading retail distribution of our PlusCBD Oil™ brand to 1,968 stores as of June 30, 2018.

*Accelerated investment to increase our operating scale to take advantage of a fast-growing market, expected to reach $1.6 billion by 2021.

*Strong trade leadership role to advocate passage of the 2018 Farm Bill to further solidify industry legal framework.

*Actively prosecuting our U.S. Patent Application No. 15/426,617 (the ‘617 Application) with plans to file and prosecute several more applications related to the ‘617 Application. Also, we have commenced foreign patent prosecution for the ‘617 Application based on our global strategy to commercialize our drug candidate CVSI-007.

*Ranking among the leading financial performers in our sector especially when measured against comparable public companies including Tilray Inc., Cronos Group Inc. and Canopy Growth Corporation.

*Submitting up-listing application with NASDAQ Capital Market, which would allow the Company to broaden our investor pool and provide greater access to capital markets.

“We sympathize with our shareholders for having to endure this short selling activity, and the manipulations and misinformation that come along with it,” stated Mr. Dowling.
“We will continue to do everything in our control to bring this activity to a halt. In the months ahead, we look forward to reporting our operating results in this fast-growing industry and providing updates on our drug development efforts.”

About CV Sciences, Inc.(CVSI)
CV Sciences, Inc. (CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc.(CVSI) has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visitingwww.cvsciences.com.

CONTACT INFORMATION:
Robert Haag
Managing Director
IRTH Communications
CVSI@irthcommunications.com
866-976-4784
Image: CV_Logo_Horizontal_black_300dpi (1).png
Source: CV Sciences, Inc.(CVSI)

CVSI needs strong news to shut down all BS mouths and resume propel a stock price higher!

Andrew Edward Left:Info, CVSI Legal team should file a lawsuit.
3316 Clerendon Rd, Beverly Hills CA. 90210
Cell 310-489-6378
Other 323-848-9010
AndrewLeft@Hotmail.com
AndrewLeft@Gmail.com

1:2000 R/S Announcement Monday AM or following days. Mark my word.

We're all lost by the "paid pumpers" on this board who were orchestrated by DRUS scam artists(CEO and IR guy).

How to spot a pump-and-dump scheme. DRUS is one of P/D penny stock run by scam artists& paid pumpers on this board. 
This is the devious practice of insiders promoting a stock – manipulating its price higher through short-term hype “pump”– and then selling out themselves at the top “dump”, leaving those who bought on the ascent with huge losses as the stock crashes. 

These amoral shareholders can use all sorts of trickery(Rehashing of Old Info) and deception to dupe the investing public into buying the penny stocks they want to cash in on. DRUS sucked its shareholders & left dry with these massive dilutions and will not be the last batch after the Sept, there will be an Oct batch to mature one and one~

DRUS authorized shares increased to 1.5 Billion. That continues to get
ripped apart further and further with major dilution and a much higher float !!!Some say no more debt
but then by some miracle there is always more debt,14 million in liabilities and continuing net losses.
which is the equivalent of 1.7 Billion More Diluted Shares At The Current Price . Sales declined at DRUS by 28.3% year over year. If the drone industry is going gangbusters, why have sales at DRUS declined by 28.3% compared to last year? This P/D penny stock isn't going anywhere but down the tubes to .0001.